[ad_1]
Bristol-Myers Squibb (BMY) closed at $ 48.07 on the last trading day, marking a -0.41% change from the previous day. This change was lower than the 0.06% gain recorded by the S & P 500 that day. At the same time, the Dow gained 0.16% and the Nasdaq, a major technology index, lost 0.13%.
Today, the shares of the biopharmaceutical company have gained 6.79% over the past month, outpacing the 2.13% loss in the medical sector and the 2.95% loss of the S & P 500 over the past month. of this period.
BMY will look to show some strength as it approaches its next release of results. The company is expected to earn $ 1.05 EPS, down 3.67% from the same quarter last year. At the same time, our latest consensus estimates are for sales of $ 5.83 billion, up 2.36% from the same quarter last year.
Consensus estimates of BMY 's Zacks for the entire year are based on earnings of $ 4.28 per share and a turnover of $ 24.07 billion. These results would represent variations of one year on the other + 7.54% and + 6.69%, respectively.
Investors may also notice recent changes made to the analyst's estimates for the BMY. These revisions generally reflect the latest short-term business trends, which can change frequently. In this spirit, we can consider revisions of positive estimates as a sign of optimism about the company's business prospects.
Based on our research, we believe that these revisions of estimates are directly related to stock movements close to the teams. Investors can benefit by using Zacks' ranking. This model takes into account these estimation changes and provides a simple and usable scoring system.
The Zacks ranking system, which ranges from # 1 (strong buy) to # 5 (strong sell), has an impressive history of unaudited outperformance, with # 1 stocks generating an average annual return of + 25% since 1988. The estimate of Zacks Consensus EPS has increased by 0.36% in the last month. BMY currently holds the rank 1 of Zacks (strong buy).
In terms of its valuation, BMY has a P / E forward ratio of 11.28. This valuation marks a discount to the average P / E of 13.92 for the industry.
Investors should also note that the BMY has a PEG ratio of 2.38 at the moment. This measure is used in the same way as the famous P / E ratio, but the PEG ratio also takes into account the expected growth rate of the security. The BMY industry had an average PEG ratio of 2 at the close of yesterday.
The large-cap pharmaceutical industry is part of the medical sector. This industry is currently ranked 33rd in the Zacks industry, placing it in the top 13% of 250 industries and more.
The Zacks Industry Ranking measures the strength of our individual industry groups by measuring the average Zacks ranking of individual actions within groups. Our research shows that the 50% of the top rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all these stock transfer steps, and more, on Zacks.com.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "
Do you want to know the latest Zacks Investment Research recommendations? Today, you can download 7 best actions for the next 30 days. Click to get this free report
& nbsp;
Bristol-Myers Squibb Company (BMY): Free Shares Analysis Report Analysis
& nbsp;
To read this article on Zacks.com, click here."data-reactid =" 30 ">
Do you want to know the latest Zacks Investment Research recommendations? Today, you can download 7 best actions for the next 30 days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Shares Analysis Report Analysis
To read this article on Zacks.com, click here.
[ad_2]
Source link